Human Leukocyte Antigens Class II Alleles Affecting the Response to 5–7 Year Antiretroviral Therapy in A Latvian Cohort

Open access

Abstract

Antiretroviral therapy (ART) aims at suppressing viral replication and strengthening immune system in patients with HIV-1. Human Leukocyte Antigens (HLA) are among factors responsible for effectiveness of ART. The aim of this study was to determine the effect of HLA Class II alleles on the response to long-time ART, assessed by a change in CD4+ T-cell count in relation to viral load. The sample included 69 patients (17 females and 52 males) aged 20 to 50 with HIV-1 infection, who were undergoing ART in the Latvian Centre of Infectious Diseases. The median period of observation was 5.7 years. CD4+ T-cell count and viral load were analysed at the baseline and end of the period of observation. HLA typing was performed by polymerase chain reaction with low resolution sequence specific primers. Multiple hierarchical linear regression analysis confirmed that an increase in HIV-1 viral load was associated with a decrease in the level of CD4+ T-cell count. In addition, HLA-DRB1*04 and HLA-DQB1*06:01 alleles contributed negatively to the level of CD4+ T-cell count.

Anonymous (2016a). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2nd edn. World Health Organization, Geneva. Available from: http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1 (accessed 14 September 2018).

Anonymous (2016b). QIAamp DNA Mini and Blood Mini Handbook. QIAGEN. Sample & Assay Technologies, 5th edn. Available from: https://www.qiagen.com/jp/resources/download.aspx?id=62a200d6-faf4-469b-b50f-2b59cf738962&lang=e (accessed 12 April 2018).

Anonymous (2018). HLA-DRB1, DQ1, DQB1 REAL-TIME PCR Genotyping Kits. DNA-Technology. Available from: http://www.dna-technology.ru/eng/dnaproducts/reagents/ (accessed 12 April 2018).

Balandraud, N., Picard, C., Reviron, D., Landais, C., Toussirot, E., Lambert, N., Telle, E., Charpin, C., Wendling, D., Pardoux, E., Auger, I., Roudier, J. (2013). HLA-DRB1 Genotypes and the Risk of Developing Anti Citrullinated Protein Antibody (ACPA) Positive Rheumatoid Arthritis. PLoS ONE, 8 (5), e64108.

Boettiger, D.C., Kerr, S., Ditangco, R., Merati, T. P., Pham, T. T. T., Chaiwarith, R., Kiertiburanaku, S., Li, C. K. P., Kumarasamy, N., Vonthanak, S., Lee C., Kinh, N. V., Pujari, S., Wong, W. W., Kamarulzaman, A., Zhang, F., Yunihastuti, E., Choi, J. Y., Oka, S., Ng, O. T., Kantipong P., Mustafa, M., Ratanasuwan, W., Sohn, A., Law, M. (2014). Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database. PLoS ONE, 9 (9), e106525.

Buck, D., Cepok, S., Hoffmann, S., Grummel, V., Jochim, A., Berthele, A., Hartung, H.-P., Wassmuth, R., Hemmer, B. (2011). Influence of the HLA-DRB1 genotype on antibody development to Interferon Beta in multiple sclerosis. Arch. Neurol., 68 (4), 480–487.

Gezie, L. D., Gelaye, K. A., Worku, A. G., Ayele, T. A., Teshome, D. F. (2017). Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia. BMC Res Notes, 10, 277.

Goronzy, J. J., Matteson, E. L., Fulbright, J. W., Kenneth J. Warrington, K. J., Chang-Miller, A., Hunder, G. G., Mason, T. G., Nelson, A. M., Valente, R. M., Crowson, C. S., Erlich, H. A., Reynolds, R. L., Swee, R. G., O’Fallon, W. M., Weyan, C. M. (2004). Prognostic markers of radio-graphic progression in early rheumatoid arthritis. Arthritis Rheum., 50 (1), 43–54.

Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbe, L., Wilkinson, G. R., Clifford, D. B., D’Aquila R. T., De Gruttola, V., Pollard, R. B., Merigan, T. C., Hirsch, M. S., George, A. L., Donahue, J. P., Kim, R. B. (2005). Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: An adult aids clinical trials group study. J. Infect. Dis., 192, 1931–1942.

Julg, B., Moodley, E. S., Qi, Y., Ramduth, D., Reddy, S., Mncube, Z., Gao, X., Goulder, P. J., Detels, R., Ndung’u, T., Walker, B. D., Carrington, M. (2011). Possession of HLA class II DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C and B infection. J. Infect. Dis., 203, 803–809.

Kapitány, A., Szabó, Z., Lakos, G., Aleksza, M., Végvári, A., Soós, L., Karányi, Z., Sipka, S., Szegedi, G., Szekanecz, Z. (2008). Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis. Israel Med. Assoc. J, 10, 32–36.

Keet, I. P. M., Tang, J., Klein, M. R., LeBlanc, S., Enger, C., Rivers, C., Apple R. J., Mann, D., Goedert, J. J., Miedema, F., Kaslow, R. A. (1999). Consistent association of HLA Class I and II and transporter gene products with progression of human immunodeficiency Virus Type 1 infection in homosexual men. J. Infect. Dis., 180, 299–309.

Keiser, O., MacPhail, P., Boulle, A., Wood, R., Schechter, M., Dabis, F., Sprinz, E., Egger, M., for the ART-LINC Collaboration of the international databases to evaluate AIDS (IeDEA) (2009). Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop. Med. Int. Health, 14 (10), 1220–1225.

Langford, S. E., Ananworanich, J., Cooper, D. A. (2007). Predictors of disease progression in HIV infection: A review. AIDS Res. Ther., 4, 11.

Lucas, G. M., Chaisson, R. E., Moore, R. D. (1999). Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med., 131, 81–87.

Lundgren, J. D., Mocroft, A., Gatell, J. M., Ledergerber, B., Monforte, A., Hermans, F., Goebel, F.-D., Blaxhult, A., Kirk, O., Phillips, A. N., for the EuroSIDA Study Group (2002). A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study. J. Infect. Dis., 185, 178–187.

Malhotra, U., Holte, S., Dutta, S., Berrey, M. M., Delpit, E., Koelle, D. M., Sette, A., Corey, L., McElrath, M. J. (2001). Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J. Clin. Invest., 107, 505–517.

Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I., Christiansen, F. T. (2002). Association between the presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 359, 727–732.

Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., Phair, J. P., Rinaldo, C. P. (1997). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med., 126 (12), 946–954.

Montarroyos, R. U., Miranda-Filho, C. D., César, C. C., Souza, W. V., Lacerda, H. R., Albuquerque, M. F. P. M., Aguiar, M. F., Ximenes, R. A. A. (2014). Factors related to changes in CD4+ T-cell counts over time in patients living with HIV/AIDS: A multilevel analysis. PLoS ONE, 9 (2), e84276.

Odafe, S., Torpey, K., Khamofu, H., Ogbanufe, O., Oladele, E. A., Kuti, O., Adedokun, O., Badru, T., Okechukwu, E., Chabikuli, O. (2012). The Pattern of Attrition from an Antiretroviral Treatment Program in Nigeria. PLoS ONE, 7 (12), e51254.

Pantaleo, G., Fauci, A. S. (1996). Immunopathogenesis of HIV infection. Annu. Rev. Microbiol., 50 (1), 825–854.

Patrikar, S., Shankar, S., Kotwal, A., Basannard, D. R., Bhattie, V., Vermaf, R., Mukherj, S. (2017). Predictors of first line antiretroviral therapy failure and burden of second line antiretroviral therapy. Med. J. Armed Forces India, 73, 5–11.

Pavlos, R., Mallal, S., Phillips, E. (2012). HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics, 13 (11), 1285–1306.

Ranasinghe, S., Cutler, S., Davis, I., Lu, R., Soghoian, D. Z., Qi, Y., Sidney, J., Kranias, G., Flanders, M. D., Lindqvist, M., Kuhl, B., Alter, G., Deeks, S. G., Walker, B. D., Gao, X., Sette, A., Carrington, M., Streeck, H. (2013). Association of HLA-DRB1–restricted CD4+ T cell responses with HIV immune control. Nat. Med., 19, 930–933.

Robbins, G. K., Daniels, B., Zheng, H., Chueh, H., Meigs, J. B., Freedberg, K. A. (2007). Predictors of antiretroviral treatment failure in an urban HIV clinic. J. Acquir. Immune Def. Syndr., 44, 30–37.

Saah, A. J., Hoover, D. R., Weng, S., Carrington, M., Mellors, J., Rinaldo, C. R., Mann, D., Apple, R., Phair, J. P., Detels, R., O’Brien, S., Enger, C., Johnson, P., Kaslow, R. A., Multicenter AIDS Cohort Study. (1998). Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. AIDS, 12 (16), 2107–2113.

Zanelli, E., Breedveld, F. C., de Vries, R. R. P. (2002). HLA association with autoimmune disease: A failure to protect? Rheumatology, 39, 1060–1066.

Zhu, P., Zhu, Q., Zhang, Y., Ma, X., Li, Z., Li, J., Chen, J., Luo, L., Ring, H. Z., Ring, R. Z., Su, L. (2013). ABCB1 variation and treatment response in AIDS patients: Initial results of the Henan Cohort. PLoS ONE, 8 (1), e55197.

Journal Information

CiteScore 2017: 0.22

SCImago Journal Rank (SJR) 2017: 0.127
Source Normalized Impact per Paper (SNIP) 2017: 0.211

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 60 60 37
PDF Downloads 58 58 41